

B-LCL-HROC112 | 302023

Description	B-LCL-HROC112	B	EBV	B	T	NK
	B-LCL-HROC112 CD19	CD20	CD23	CD80	B	MHC
	B-LCL-HROC112	IgG	IgM	IgA		

Organism

Tissue

Disease

Metastatic site Not applicable (EBV-transformed B-LCL from CRC patient; suspension culture)

Applications T cell and NK cell assays; HLA typing; antigen presentation studies; CTL assay target cells; colorectal cancer immunology; patient-matched HROC biobank studies

Synonyms B-LCL CO112 Bc HROC112

Age 80

Gender

Ethnicity Caucasian

Morphology

Cell type B

Growth properties

Citation B-LCL-HROC112 Cytion 302023

B-LCL-HROC112 | 302023

Biosafety level 2

NCBI_TaxID 9606

CellosaurusAccession Not assigned

GMO Status GMO-S2: This B-LCL contains a stably maintained EBV episome (EBNA-1/-2/-3, LMP-1/-2). EBV is classified as risk group 2; BSL-2 containment required. This classification applies within Germany; regulations may differ elsewhere.

Viruses EBV

Culture Medium RPMI1640 w 2.0mM w 2.0g/L NaHCO3 Cytion article number 820700a

Supplements 10% FBS

Subculturing ⁵ /ml 1ml 1×10

Freeze medium FBS 10 DMSO

CM-1

B-LCL-HROC112 | 302023

Thawing and Culturing Cells				
1.				
2.		-150		3
3.		37		40 60
4.	70			
5.		8ml	15ml	
6.	300 x g 3			
7.	10ml		2 T25	
8.				

Incubation Atmosphere 37 5% CO₂

Flask Coating

Freezing Procedure -78

Shipping Conditions -78

Storage Conditions -150 -196 80

HLA

Sterility PCR